NERVIANO, May 17th 2023 – Nerviano Medical Sciences Srl (NMS Srl), a member of NMS Group, the largest oncological R&D company in Italy, focused on the discovering and developing innovative therapies for the treatment of cancer, today announced that Paramjit Kaur, PhD has joined the Global Asset Leadership Team to lead the strategy and the development of clinical PERK/GCN2 asset currently in phase 1.
Dr. Kaur is a highly experienced drug development project leader with proven track record in clinical development, clinical operations, medical affairs, alliance, and project management spanning multiple therapeutic areas and experiences in regulatory filing and product launch experiences.
“We are excited to have Pam join our Asset Leadership Team”, said Alessia Montagnoli, Global Head of Asset Leadership of NMS Srl. “With her strong and wide experience in project leadership in drug development and her proven track record of success, Pam will be invaluable in our driving the rapid advancement of this crucial NMS asset.”
Dr. Kaur commented: “I am excited to lead the PERK/GCN2 asset with first-in-class potential, offering novel treatment options to address high unmet needs of patients. I am delighted to be part of the team that is shaping and implementing NMS’ innovative strategies to the increasingly competitive pipeline.”
Dr. Kaur’s was most recently a Global Asset Leader for the Asparaginases program at Servier, where she brought registration to new formulations of Oncaspar. She previously served as Global Project Leader for Bavencio (anti-PDL1) combinations at EMD Serono (a division of Merck KGaA), within the Pfizer Alliance. Previously, she has held roles in Global Medical Affairs and Clinical Trial Leadership at Alcon Research/Novartis for Ophthalmology, Otic, and Allergy therapeutic areas.
She will be based in Boston, working from the U.S. subsidiary (Nerviano Medical Sciences, Inc./ NMS-US).
Press Release Link:NMS Srl-Pam Kaur appointed to lead PERK and GCN2
from NMSGroup
